Synthesis of Novel Hybrid Lonidamine-Coumarin Derivatives and Their Anticancer Activities


Ipek Ö., SUCU B. O., GÜL Ş., YOLAÇAN Ç., GÜZEL M.

Journal of Molecular Structure, vol.1281, 2023 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 1281
  • Publication Date: 2023
  • Doi Number: 10.1016/j.molstruc.2023.135114
  • Journal Name: Journal of Molecular Structure
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core, INSPEC
  • Keywords: Anti-cancer activity, Coumarin, Drug discovery, Lonidamine
  • Istanbul Medipol University Affiliated: Yes

Abstract

In order to develop drugs against cancer, which is one of the deadliest diseases in the world, hybridizing structures with known anticancer activity can provide a dual activity for the treatment of cancer cases. For this purpose, a series of novel hybrid compounds combining lonidamine and 7-hydroxy-4-methylcoumarin via different linker modifications have been synthesized in this study. The chemical structures of the novel compound were elucidated with 1H and 13C NMR and mass spectrometry (HRMS) methods. All the synthesized compounds were screened for anticancer activity against MCF-7 and A549 cells. Among them, compound 2 appeared to be the most potent compound on MCF-7 lines; and IC50 dose was determined as 33.12 µM. IC50 of Compound 6 was determined as 139.6 µM for A549 cells. Considering anticancer activity studies, compounds 2 and 6 have potential to lead to the development of novel hybrid compounds for cancer therapy. Further studies to identify mechanistic explanations of the bioactivity of these molecules are ongoing and will be reported in due course.